Category: Abbott Laboratories
Abbott launches a Japanese clinical trial to compare the fully bioresorbable Absorb vascular scaffold against its own line of Xience drug-eluting stents in hope of winning Japanese regulatory approval.
Abbott (NYSE:ABT) kicked off the aptly-named ABSORB trial in Japan to compare its "dissolving" vascular scaffold with its metallic drug-eluting stent in patients with coronary artery disease (CAD).
Abbott OKs a $3 billion share repurchasing program, on the heels of a just-completed $5 billion stock buyback, and announces its 358th consecutive quarterly dividend.
Abbott (NYSE:ABT) said its board of directors approved a $3 billion share repurchasing program.
The new plan replaces a $5 billion share buyback first OK'd in October 2008, which was just completed, according to a press release.
Despite the billions in profits garnered in Ireland, medical device companies Abbott and Boston Scientific paid almost no taxes in the Emerald isle in 2011, the Irish Times reports.
MassDevice columnist Stephen Simpson on rumors that Valeant may be prepping a $9 billion bid for Bausch+Lomb
By Stephen Simpson
Never let it be said that Valeant (NYSE: VRX) management is shy about doing deals. With a roster of past deals including Biovail, Cephalon, OraPharma, and Medicis, Valeant claims that better than 80% of its deals have attained the 20% internal return target it uses to evaluate potential transactions. If rumors out Friday prove true, Valeant is about to bag its biggest target yet in what would be a particularly bold move.
Illinois healthcare giant Abbott lands European regulatory approval for the Xience Xpedition 48, which it calls the "world's longest coronary drug-eluting stent."
Healthcare giant Abbott (NYSE:ABT) won European regulatory approval for its Xience Xpedition 48, which it calls the world's longest coronary drug-eluting stent.
Stentys launches a clinical trial aimed at backing a pre-market approval application with the FDA for its self-apposing coronary stent.
Stentys SA (EPA:STNT) hoping a new U.S. clinical trial will help it win pre-market approval for a self-apposing coronary stent.
The Princeton, N.J.- and Paris-based medical device company said it enrolled the 1st patient in its Apposition V trial, under an investigational device exemption from the U.S. watchdog agency.
The FDA slaps its highest-risk classification on Abbott Labs' FreeStyle InsuLinx blood glucose meter recall.
The FDA slapped its highest-risk label on Abbott's (NYSE:ABT) blood glucose meter recall, deeming the software glitch potentially deadly for patients.
Abbott last month said that it had already issued a free software update to patch the problem, which may affect as many as 50,000 FreeStyle InsuLinx blood glucose meters on the market.
